Oral matrix tablet formulations for concomitant controlled release of anti-tubercular drugs: design and in vitro evaluations.
The aim of the present investigation was to develop controlled release (C.R.) matrix tablet formulations of rifampicin and isoniazid combination, to study the design parameters and to evaluate in vitro release characteristics. In the present study, a series of formulations were developed with different release rates and duration using hydrophilic polymers hydroxypropyl methylcellulose (HPMC) and hydroxypropyl cellulose (HPC). The duration of rifampicin and isoniazid release could be tailored by varying the polymer type, polymer ratio and processing techniques. Further, Eudragit L100-55 was incorporated in the matrix tablets to compensate for the pH-dependent release of rifampicin. Rifampicin was found to follow linear release profile with time from HPMC formulations. In case of formulations with HPC, there was an initial higher release in simulated gastric fluid (SGF) followed by zero order release profiles in simulated intestinal fluid (SIFsp) for rifampicin. The release of isoniazid was found to be predominantly by diffusion mechanism in case of HPMC formulations, and with HPC formulations release was due to combination of diffusion and erosion. The initial release was sufficiently higher for rifampicin from HPC thus ruling out the need to incorporate a separate loading dose. The initial release was sufficiently higher for isoniazid in all formulations. Thus, with the use of suitable polymer or polymer combinations and with the proper optimization of the processing techniques it was possible to design the C.R. formulations of rifampicin and isoniazid combination that could provide the sufficient initial release and release extension up to 24h for both the drugs despite of the wide variations in their physicochemical properties.
Hiremath
Praveen S
PS
Pharmacy Group, Birla Institute of Technology and Science, Pilani, Rajasthan, India. phiremath@pharm-int.com
Saha
Ranendra N
RN
D000284:Administration, Oral; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000737:chemistry*; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D007538:Isoniazid / Q000008:administration & dosage / Q000737:chemistry*; D012293:Rifampin / Q000008:administration & dosage / Q000737:chemistry*; D012995:Solubility; D013607:Tablets; D013678:Technology, Pharmaceutical / Q000379:methods*
D000995:Antitubercular Agents; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D013607:Tablets; D007538:Isoniazid; D012293:Rifampin